BioSymetrics, a biomedical artificial intelligence company has entered a collaboration with Sema4, a patient-centered health intelligence company, and Janssen Pharmaceuticals, Inc. The collaboration will focus on predicting the onset and severity of COVID-19 among different populations using machine learning. The parties will use BioSymetrics’ Contingent-AI engine across several projects to characterize high-risk populations, measure and predict disease progression based on biological r...